Interestingly, combinatorial inhibition of IDO1, IDO2, and TDO2 (together thought to be the predominant rate-limiting enzymes for the kynurenine pathway) did not impact tumor viability in patient derived GBM cells [55]. This evidence concerns the gene IDO1 and neoplasm.